The latest Shire Pharmaceuticals financial review states that the company’s latest ADHD medication Vyvanse is up 19 percent, mostly due to the US ADHD market increasing by 6 percent in 2013. However, the company reports a 12 percent decline in sales for ...
from Meta Search Alerts http://ift.tt/1jFa526
via IFTTT
from Meta Search Alerts http://ift.tt/1jFa526
via IFTTT
No comments:
Post a Comment